Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.52 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557356 | 1.00 | PDE4B (0.52) | PDE4BTACR1DPP4RORCGPR119 | |
| SCHEMBL557355 | 1.00 | PDE4B (0.52) | PDE4BTACR1DPP4RORCGPR119 | |
| SCHEMBL16108740 | 0.89 | PDE4B (0.60) | PDE4BTACR1 | |
| SCHEMBL16108739 | 0.89 | PDE4B (0.60) | PDE4BTACR1 | |
| SCHEMBL3697373 | 0.87 | TACR1 (0.53) | PDE4BTACR1RORCGPR119MMP13 | |
| SCHEMBL14403373 | 0.87 | TACR1 (0.53) | PDE4BTACR1RORCGPR119MMP13 | |
| SCHEMBL4760975 | 0.87 | TACR1 (0.53) | PDE4BTACR1RORCGPR119MMP13 | |
| SCHEMBL951494 | 0.87 | TACR1 (0.53) | PDE4BTACR1RORCGPR119MMP13 | |
| SCHEMBL1751275 | 0.87 | TACR1 (0.53) | PDE4BTACR1RORCGPR119MMP13 | |
| SCHEMBL951268 | 0.87 | TACR1 (0.53) | PDE4BTACR1RORCGPR119MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319300-B2 | Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof | GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200165229-A1 | POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF | GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| WO-2018137555-A1 | POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUND DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF | 浙江大学 | 2018-08-02 | — | — | WO | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165229-A1 | POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF | BPHL, AR, FRK | PDE4B 3151/4885TACR1 2173/4885DPP4 4052/4885 |
| US-11319300-B2 | Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof | AKT1, AKT2, AKT3 | PDE4B 2775/4885TACR1 1753/4885DPP4 4368/4885 |
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | PDE4B 357/4885TACR1 205/4885DPP4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.